TITLE

Talactoferrin improved survival for patients with metastatic renal cell carcinoma

AUTHOR(S)
Rini, Brian
PUB. DATE
September 2008
SOURCE
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p18
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on a study which demonstrated the effectiveness of talactoferrin in improving survival for patients with metastatic renal cell carcinoma. Participants in the study were given an oral dose of 1.5 grams of talactoferrin twice daily for 12 weeks, followed by a two-week break. According to researchers from The University of Texas M. D. Anderson Cancer Center, the University of Chicago Medical Center and other institutions, at least one adverse event occurred in 42 patients.
ACCESSION #
34154540

 

Related Articles

  • Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.  // Current Medical Literature: Kidney Cancer;Jun2010, Vol. 2 Issue 2, p55 

    The article discusses a study that investigates the safety and feasibility of using neoadjuvant sorafenib for patients with stage II or higher cell carcinoma. It states that 30 patients are treated with sorafenib for a median of 33 days before proceeding to nephrectomy. It reveals that 17 have...

  • Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.  // Current Medical Literature: Kidney Cancer;Jun2010, Vol. 2 Issue 2, p49 

    The article discusses a study on the efficacy of pazopanib in the treatment of patients with metastatic renal cell carcinoma (mRCC). It notes that the occurrence of mRCC is driven by mutation or silencing of the von Hippel-Lindau gene. In response, pazopanib is one of the targeted therapies that...

  • Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Thompson Coon, J. S.; Liu, Z.; Hoyle, M.; Rogers, G.; Green, C.; Moxham, T.; Welch, K.; Stein, K. // British Journal of Cancer;7/21/2009, Vol. 101 Issue 2, p238 

    Background:Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-α...

  • Novel Treatments.  // Current Medical Literature: Kidney Cancer;Mar2010, Vol. 2 Issue 1, p14 

    The article presents abstracts on medical topics which include the study on the use of axitinib in the treatment of refractory metastatic renal cell carcinoma and the new methods for renal cell carcinoma treatment.

  • Pazopanib.  // Current Medical Literature: Kidney Cancer;Jun2010, Vol. 2 Issue 2, p51 

    The article discusses a study which highlights the vital role of pazopanib for treatment of patients with metastatic renal cell carcinoma (mRCC). It states that pazopanib was approved by the U.S. Food and Drug Administration (FDA) for treatment of RCC. It demonstrates the strong capacity of...

  • Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.  // Current Medical Literature: Kidney Cancer;Jun2010, Vol. 2 Issue 2, p53 

    The article discusses a study which examines the efficacy of erlotinib in patients with metastatic papillary histology renal cell carcinoma (RCC) using the Phase II trial. It notes that the response of 45 patients who received erlotinib in 28-day cycles was assessed every eight weeks. It reveals...

  • Sunitinib cost effective for renal cancer.  // PharmacoEconomics & Outcomes News;7/14/2007, Issue 532, p8 

    The article discusses a study on the cost-effectiveness of sunitinib in metastatic renal cell cancer (RCC). Two Markov models were used to evaluate the cost effectiveness of sunitinib. At the Annual Meeting of the American Society of Clinical Oncology, it was found out that sunitinib is more...

  • Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Negrier, S.; Jäger, E.; Porta, C.; McDermott, D.; Moore, M.; Bellmunt, J.; Anderson, S.; Cihon, F.; Lewis, J.; Escudier, B.; Bukowski, R. // Medical Oncology;Sep2010, Vol. 27 Issue 3, p899 

    Before the development of targeted therapies, administration of cytokines (e.g., interleukin-2, interferon-α) was the primary systemic treatment option for advanced renal cell carcinoma. Sorafenib, an oral targeted, multikinase inhibitor, significantly prolonged progression-free survival and...

  • Treatment of metastatic renal cell carcinoma. Reeves, David J.; Liu, Chin Y. // Cancer Chemotherapy & Pharmacology;Jun2009, Vol. 64 Issue 1, p11 

    To review the treatment of metastatic renal cell carcinoma (RCC), including the use of new targeted therapies. A search of MEDLINE (1966 to August 2008) and American Society of Clinical Oncology Meeting abstracts (2005 to May 2008) was preformed using the search terms bevacizumab, everolimus,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics